The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Clinical outcomes of erlotinib, gefitinib, or pemetrexed in patients with non-squamous, non-small-cell lung cancer

비편평세포, 비소세포폐암 환자에서 erlotinib, gefitinib 및 pemetrexed의 효과

  • Yoon, La-Young (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Yang, Mi-Yean (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Yun, Jin-A (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Kim, Hyun-Jung (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Kim, Han-Jo (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Kim, Kyung-Ha (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Kim, Se-Hyung (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Lee, Sang-Cheol (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Kim, Chan-Kyu (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Lee, Nam-Su (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Park, Sung-Kyu (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Lee, Kyu-Taek (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Won, Jong-Ho (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Park, Hee-Sook (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine) ;
  • Hong, Dae-Sik (Department of Internal Medicine, Division of Hematology and Oncology, Soonchunhyang University College of Medicine)
  • 윤라영 (순천향대학교병원 혈액종양내과) ;
  • 양미연 (순천향대학교병원 혈액종양내과) ;
  • 윤진아 (순천향대학교병원 혈액종양내과) ;
  • 김현정 (순천향대학교병원 혈액종양내과) ;
  • 김한조 (순천향대학교병원 혈액종양내과) ;
  • 김경하 (순천향대학교병원 혈액종양내과) ;
  • 김세형 (순천향대학교병원 혈액종양내과) ;
  • 이상철 (순천향대학교병원 혈액종양내과) ;
  • 김찬규 (순천향대학교병원 혈액종양내과) ;
  • 이남수 (순천향대학교병원 혈액종양내과) ;
  • 박성규 (순천향대학교병원 혈액종양내과) ;
  • 이규택 (순천향대학교병원 혈액종양내과) ;
  • 원종호 (순천향대학교병원 혈액종양내과) ;
  • 박희숙 (순천향대학교병원 혈액종양내과) ;
  • 홍대식 (순천향대학교병원 혈액종양내과)
  • Received : 2010.06.02
  • Accepted : 2010.07.30
  • Published : 2010.10.01
⟨ Previous Next ⟩

Abstract

Background/Aims: This study compared the clinical benefits of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) with pemetrexed to identify the clinical parameters that correlated with response. Methods: A retrospective chart review examined patients who were 1) treated with EGFR TKI or pemetrexed, 2) diagnosed with advanced non-squamous non-small-cell lung cancer, and 3) previously treated with platinum-based chemotherapy in Soonchunhyang Bucheon Hospital. Results: Sixty-one patients (18 erlotinib, 18 gefitinib, 25 pemetrexed) were investigated from February 2002 to August 2009. The median follow-up period was 37 months (7~97 months). Overall, their median age was 63 years, 41 patients were non-smokers, 57 patients had adenocarcinoma, and 55 patients were at stage IV. Twenty-one patients received the study drugs as second-line chemotherapy, and others as third-line or more. No significant differences in the overall response rate (erlotinib 33.3% vs. gefitinib 38.9% vs. pemetrexed 20.0%) and progression-free survival (erlotinib 1.9 months vs. gefitinib 3.0 months vs. pemetrexed 2.9 months) were found among the three groups. Female gender was related to a good response to EGFR TKIs (p=0.047). Skin rash in the erlotinib group (p=0.037) and adenocarcinoma in the pemetrexed group (p=0.02) were related to improved progression-free survival. Few side effects were reported. Conclusions: Both EGFR TKIs and pemetrexed therapy for non-squamous non-small-cell lung cancer were efficient and tolerable after the failure of first-line platinum-based chemotherapy. Further prospective studies are needed to validate the predictive role of the suggested clinical parameters in this study.

목적: 본 연구는 비소세포폐암의 2차 이상의 항암 화학요법에서 EGFR TKIs와 pemetrexed의 임상적인 특징에 따른 치료 성적을 비교함으로써 구제치료의 선택에 도움을 주고자 하였다. 방법: 2002년 2월부터 2009년 8월까지 부천 순천향대학교 병원 혈액종양내과에서 비소세포폐암을 진단받은 환자들 중 편평상피암을 제외한 선암과 대세포암 환자들을 대상으로 하였으며 이들 중 gefitinib이나 erlotinib 및 pemetrexed로 치료받은 환자를 의무기록을 통해 후향적으로 조사하였다. 결과: 총 61명이 연구에 참여하였고 그 중 erlotinib군이 18명, gefitinib군은 18명, pemetrexed군은 25명이었으며 중앙관찰기간은 37개월(7-97개월)이었다. 세 군간에 반응율과 무진행 생존기간에는 의미있는 차이가 없었으며 EGFR TKIs 를 투여받은 환자들 중에서는 여성에서 보다 좋은 반응율은 보였고, erlotinib 을 투여받은 환자들 중 피부발진이 있었던 환자들과 Pemetrexed를 투여 받은 환자들 중 선암으로 진단된 경우 에서 무진행 생존기간이 의미있게 길었다. 결론: EGFR TKIs 와 Pemetrexed 는 모두 비편평세포암, 비소세포암 환자에서 2차 이상의 치료로 사용하였을 때 비교적 효과적이었으며 부작용도 적은 것으로 나타났다. 향후 EGKR TKIs 및 pemetrexed군 치료 효과 및 치료 효과에 영향을 미치는 다양한 임상적 예후인자에 대한 보다 많은 대규모 전향적 비교 연구가 필요할 것이다.

Keywords

References

  1. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell cancer. Lung Cancer 67:257-274, 2010 https://doi.org/10.1016/j.lungcan.2009.10.012
  2. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 Study. J Clin Oncol 28:49-55, 2010 https://doi.org/10.1200/JCO.2009.22.9427
  3. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353, 2004 https://doi.org/10.1200/JCO.2004.09.053
  4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000 https://doi.org/10.1200/JCO.2000.18.10.2095
  5. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000 https://doi.org/10.1200/JCO.2000.18.12.2354
  6. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani C P, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158, 2003 https://doi.org/10.1001/jama.290.16.2149
  7. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809-1818, 2008 https://doi.org/10.1016/S0140-6736(08)61758-4
  8. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 https://doi.org/10.1200/JCO.2004.08.163
  9. Rudd RM, Gower NH, Spiro SG, Eisen TG, Harper PG, Littler JA, Hatton M, Johnson PW, Martin WM, Rankin EM, James LE, Gregory WM, Qian W, Lee SM. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non small cell lung cancer. a phase III randomized study of the London Cancer Group. J Clin Oncol 23:142-153, 2005 https://doi.org/10.1200/JCO.2005.03.037
  10. Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B, Guaraldi M, Palomba G, Preti P, Petralia A, Artioli F, Picece V, Farris A, Mantovani L. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 41:81-92, 2005 https://doi.org/10.1016/j.ejca.2004.08.029
  11. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247, 2004 https://doi.org/10.1200/JCO.2004.11.057
  12. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK. Predictive and prognostic impat of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501, 2005 https://doi.org/10.1200/JCO.2005.01.388
  13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 https://doi.org/10.1056/NEJMoa040938
  14. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 https://doi.org/10.1126/science.1099314
  15. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 https://doi.org/10.1073/pnas.0405220101
  16. Park K, Goto K. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 22:561-573, 2006 https://doi.org/10.1185/030079906X89847
  17. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009 https://doi.org/10.1056/NEJMoa0810699
  18. Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 16:780-785, 2005 https://doi.org/10.1093/annonc/mdi157